Article Sidebar

PDF
Date Published: 23/09/2022
Abstract Views: 148
Views PDF: 107
DOI: https://doi.org/10.51298/vmj.v518i1.3384
Issue
Vol. 518 No. 1 (2022)
Section
Các bài báo
How to Cite
Thanh Đức, L. ., & Thị Thu Hoài, B. . (2022). OVERALL SURVIVAL AND SOME FACTORS AFFECTING IN STAGE IV LUNG CANCER TREATED ANTI-EGFR AFTER FIRST-LINE CHEMOTHERAPY. Vietnam Medical Journal, 518(1). https://doi.org/10.51298/vmj.v518i1.3384

OVERALL SURVIVAL AND SOME FACTORS AFFECTING IN STAGE IV LUNG CANCER TREATED ANTI-EGFR AFTER FIRST-LINE CHEMOTHERAPY

Lê Thanh Đức1,, Bùi Thị Thu Hoài1
1 Vietnam National Cancer Hospital

Main Article Content

Abstract

Aims: Evaluation of the overall survival time and some factors affecting the overall survival in stage IV non-small cell lung cancer patients treated with anti-EGFR after first-line chemotherapy. Research subject: 40 patients were diagnosed stage IV non-small cell lung cancer, received oral erlotinib after 4-6 cycles platinum-containing regimen chemotherapy at National Cancer Hospital from January 2016 to June 2022. Patients and Methods: Retrospective combined prospective study. Results: The average OS was 29,4 ± 2,4 months, the median OS was 27 ± 4,5 months. Higher OS in patients have EGFR-mutated gene in exon 19 and skin side effects in patients with NSCLC. Conclusion: Erlotinib improves overall survival and is related to EGFR mutation site and skin side effects.

Article Details

Keywords

Overall survival, factors affecting, lung cancer, anti-EGFR

References

1. Schiller J.H, Harrington, D, Belani, C.P, Langer, C, Sandler, A, Krook, J, Zhu, J, Johnson, D.H (2002), Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med. 346, 92-98
2. Crino L, Mosconi AM, Scagliotti G, et al (1999), Gemcitabine as second- line treatment for advanced non-small-cell lung cancer: A phase II trial., J Clin Oncol. 17, 2081-2085.
3. Pallis A.G, Serfass, L, Dziadziusko, R, van Meerbeeck, J.P, Fennell, D, Lacombe, D, Welch, J, Gridelli, C (2009), Targeted therapies in the treatment of advanced/metastatic NSCLC, Eur. J. Cancer,. 45, 24732487.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005), Erlotinib in previously treated non-small-cell lung cancer., N Engl J Med 353, 123-132.
5. Urata Y, Katakami N, Morita S. et al (2016), Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L, J Clin Oncol. 34(27), 3248-57.
6. W. D. Travis, E. Brambilla, A. G. Nicholson, et al. The 2015 World HealthOrganization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. 2015; J Thorac Oncol, 10(9), 1243-1260.
7. Zhou C, Wu YL, Chen G, et al (2011), Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735-724.
8. Zhou C, Wu YL, Chen G et al (2011), Updated efficacy and quality-oflife (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non- small cell lung cancer (NSCLC) J Clin Oncol. 29(Suppl 15), 7520.
9. Lê Thu Hà, Trần Văn Thuấn. Đánh giá hiệu quả thuốc erlotinib trong điều trịung thư phổi biểu mô tuyến giai đoạn muộn. 2017; Tạp chí Y học thực hành, 993, 53-55.
10. Lee S. M, Khan I, Upadhyay S et al (2012), First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial, Lancet Oncol. 13(11), 1161-70.